CROMSOURCE Acquires Pleiad: Expands US Coverage
CROMSOURCE, an international full service contract research organization (CRO) announced the acquisition of Pleiad, an international CRO with offices in the United States (Cambridge, Mass.) and United Kingdom (Stirling, Scotland).
Pleiad was launched in 1999, supporting clients in multiple therapy areas and with dedicated Medical Device and Ophthalmology Divisions. Additionally,Pleiad also encompasses particularly strong capabilities within statistics and data management.
"We are delighted to welcome Pleiad and its expert team," stated Dr Oriana Zerbini, Chief Executive Officer of CROMSOURCE. "For some time we have wanted to expand and consolidate our presence in the United States and we have now found the perfect way to do so. The opportunity to further add to our UK team and expand our team of experts in data management and statistics is also of great importance to us. With this collaboration CROMSOURCE reinforces its capability to support our clients with even the largest of development programmes in both Europe and the United States."
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
